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In the choice of, or switch between, various inhaled corticosteroids (ICS) it is important to
know equipotent doses for clinical treatment effects of the alternatives. Various ICS do
have different inherent potency. Further, the ICS are delivered from inhalers that may
differ markedly in output characteristics and drug delivery to intrapulmonary airways.
Therefore, clinical efﬁcacy comparisons must include drug–inhaler comparisons.
We estimated the therapeutic potency ratio of the Flixotide Diskus (ﬂuticasone
propionate, FP) and the Pulmicort Turbuhaler (budesonide, BUD) in steroid-naive asthma
patients, using a dose-reduction technique (FP 500-0mcg/day, BUD 800-0mcg/day). The
dose deﬁning end point was loss of asthma control in this paper denoted as exacerbation.
In total, 282 patients with proven asthma were enrolled in the study, and 103 in the FP
group and 98 in the BUD group completed the study per protocol.
In total, 80 patients in the FP-group and 79 in the BUD-group experienced a dose deﬁning
exacerbation. The exacerbation frequency increased in a dose-dependent way as the dose
was titrated down. From these data the potency difference between the present drug
inhaler combinations, Flixotide Diskus and Pulmicort Turbuhaler, was calculated to be
between 1.50:1 (95% CI 1.10:1–2.05:1) and 1.75:1 (CI 1.26:1–2.43:1) depending on if
patients with insufﬁcient steroid-response were excluded from the calculations or not. In
these steroid-naı¨ve patients, the potency difference was evident only at low daily doses,
below 200mcg.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
4 231 75; fax: +46 3182 4904.
lungall.gu.se (B.-E. Skoogh).
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Inhaled corticosteroids (ICS) are recommended as a ﬁrst-line
maintenance treatment of persistent asthma. In the choice
of, or switch between, various ICS it is important to know
equipotent doses for clinical treatment effects of the
alternatives. Various ICS do have different inherent potency.
Further, the ICS are delivered from inhalers that may differ
markedly in output characteristics and drug delivery to
intrapulmonary airways.1,2 Therefore, clinical efﬁcacy com-
parisons must encompass the drug–inhaler combinations.
The study design of the comparison is also of decisive
importance. In a recent editorial, Beasley et al.3 argued
against the value of comparative efﬁcacy studies based on
single high-dose comparisons. Instead they recommended
dose response comparisons including doses below the top of
the dose response curves and suggested three different
study designs4 for such comparisons, one of which was a
dose down-titration technique.
The aim of this study was to estimate the therapeutic
potency ratio of the Flixotide Diskus (ﬂuticasone propio-
nate, FP) and the Pulmicort Turbuhaler (budesonide, BUD) in
steroid-naive asthma patients, using a dose-reduction
technique with loss of asthma control, denoted ‘‘exacerba-
tion’’, as the primary, dose deﬁning end point.Methods
Study design
At 24 Swedish Primary Health Care Centres, steroid-naive
asthmatics were randomized centrally to double-blind,
double-dummy ICS treatment. During a run-in period of 2
weeks the diagnosis was conﬁrmed by reversibility testing
and recordings of symptom scores and rescue medication.
The only treatment allowed during the run-in was rescue
medication with salbutamol inhalation. After run-in the
patients were allocated to treatment according to a
centralised randomization schedule choosing the lowest
available pack number. The ICS treatment was initiated with
either 250 (metered dose) mcg BID of FP or 400 (metered
dose) mcg BID of BUD for 12 weeks. These initial doses were
chosen according to available data in the literature.5–7 TheD
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Figure 1 Schematic depiction of the studdose was then reduced in a stepwise fashion every 8 weeks
(Fig. 1) until an exacerbation was registered according to
predetermined criteria, at which point the patient was
withdrawn from the study. The ﬁrst 4 weeks during step 1
were assigned to establish the treatment effect and no
patient was excluded because of an exacerbation during this
period.
Study population
Asthma patients of at least 16 years of age were eligible for
the study if they had not used any steroids for the last 3
months, if forced expiratory volume (FEV1) was 470%
predicted normal after salbutamol inhalation, and if they
at least once a week for the last 2 months had had asthma-
related symptoms such as disturbing cough without infection
and/or episodes of wheezing and/or episodes of chest
tightness and/or awakening with chest symptoms. Further,
within 2 months before randomization they should show
improvement on salbutamol inhalation of FEV1 (X15%) or of
peak expiratory ﬂow (PEF) (X60 L/min) or show a PEF
variability of X20% and during run-in have a cumulative
symptom score X7 during (see below) last 10 days and/or
need rescue medication X3 days/week.
Patients were not eligible if they had another signiﬁcant
disease or were pregnant, or if they needed oral steroids or
used cromoglycate, long-acting beta-agonists, antileuko-
triens, beta blockers or ACE-inhibitors. All patients gave
written informed consent and the study was approved for
each centre by the ethics committee.
Assessments and outcome measures
The primary outcome was the lowest effective dose deﬁned
as the dose just above that at which asthma control was
lost. The number of patients who could quit inhaled
steroids, FEV1, PEF, day-time and night-time symptoms
scores and use of rescue medication were assessed as
descriptive measures or to diagnose loss of asthma control,
in this paper denoted as exacerbation.
Clinic visits were scheduled at weeks 2, 0, 4, 8, 12 and
then every 8 weeks up to week 44 or until the patient was
withdrawn from the study. At each visit during the28 36 44
ek
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peak ﬂow meter) was performed in triplicate. The occur-
rence of any adverse event was also recorded.
The patients completed daily record cards on intake of
study medication, morning and evening PEF, use of rescue
medication, and day-time and night-time asthma symptom
scores. Night-time symptoms were scored from 0 (no
symptoms) to 4 (symptoms so severe I did not sleep at
all), and daytime symptoms from 0 (no symptoms) to 5
(symptoms so severe that I could not go to work or perform
normal daily activities). Base-line values were calculated
from recordings during week 4 as follows: PEF—mean of the
three best morning recordings before any possible rescue
medication; rescue medication—the second highest use
during night-time and day-time, respectively; symptom
score—the second highest score for night-time and day-
time scores, respectively. If these values improved further
until week 12 (the last week during step 1), the correspond-
ing values from this week were used as base-line values for
the following dose steps. The second highest value was used
to reduce the inﬂuence from single out-lying values.
An exacerbation was diagnosed if one or more of the
following criteria were fulﬁlled:1.
Table 1 Patient characteristics during run-in.
FP BUDDecrease of PEF—one episode with a critical low value as
judged by a physician or morning PEF o85% for 3 days in
a row and/or morning PEF o85% for 4 out of 7 days.(n ¼ 116) (n ¼ 113)2.Age, years (mean7SD) 40714 38714Increase of rescue medication—X3 doses/day for 3 days
in a row or X3 doses/day on four out of 7 days, or
X1 dose/night for two nights in a row.Female, n (%) 65 (56) 64 (57)3.Male, n (%) 51 (44) 49 (43)
Clinic FEV1
, L (mean7SD) 3.170.87 3.070.78
Clinic FEV1
, % pred
(mean7SD)
91717 88717
Morning PEF, L/min
(mean7SD)
4337105 4297100
Total symptom score/24 h
(mean7SD)
2.1371.3 1.971.2
Rescue inhalations/24 h
(mean7SD)
2.672.2 2.472.1Increase of symptom score—by 2 units/day for three days
in a row, or by 2 units/day on four out of 7 days, or by 1
unit/night for two nights in a row.
If the exacerbation criteria were associated with symp-
toms of infection, two exacerbations within 6 weeks were
necessary to deﬁne the lowest efﬁcient maintenance dose.
It was allowed to treat infectious exacerbations with oral
prednisolone, 30mg daily, until recovery of PEF (X90%
baseline), rescue medication and symptoms. Antibiotics
were allowed at the discretion of the physician.Reported values are before inhalation of beta-2-agonists.
Table 2 Effect of treatment by inhaled steroids as
reﬂected by change in group mean values from run-in to
end of step 1.
Mean7SD Change
FP
(n ¼ 113)
BUD
(n ¼ 105)
Clinic FEV1
, L 0.2270.44 0.1370.46
Morning PEF, L/min 40.6749.1 39.4745.9
Total symptom score/
24 h
1.2971.38 1.1571.48
Rescue inhalations/24 h 1.7872.03 1.6771.99
Reported values are before inhalation of beta-2-agonists.Statistical analysis
The primary analysis is the potency ratio between least
efﬁcient dose for BUD and FP. To be able to estimate the
conﬁdence interval for the median of the potency ratio the
following calculations were used: Assuming that X is least
efﬁcient dose (40) for BUD and Y is the corresponding
stochastic variable for FP, the potency ratio between BUD
and FP, X=Y can be expressed as exp (log Xlog Y). If the
distributions of X and Y are lognormal distributed then an
estimation and 95% conﬁdence interval for mean and median
of logXlog Y can easily be calculated using normal theory.
The median and 95% conﬁdence interval for the potency
ratio BUD/FP ðX=YÞ was calculated by taking the antiloga-
rithm of the above estimates.8
Assuming potency ratios of 1.5; 2.0; 2.5 we calculated
that 2 110 patients would yield a 95% CIs of 1.17–1.93;
1.55–2.57; 1.94–3.22, respectively ,which we considered tobe acceptable. To get 220 evaluable patients we decided to
include 280 patients.
The improvement of lung function, symptom scores and
use of rescue medication between end of step 1 and run-in
was analyzed by the Wilcoxon signed rank. To describe these
improvements mean and standard deviation of the differ-
ence between end of step 1 and run-in was used. Dose
dependency was tested by repeated measurement analysis
using generalized estimating equations (GEE) logistic regres-
sion.
Results
Patient characteristics during run-in and base line
In total, 282 patients were recruited to the run-in phase. Of
these 50 did not fulﬁll the run-in criteria and 3 were
randomized in spite of not fulﬁlling all criteria. Thus, 229
patients entered the double-blind treatment phase per
protocol. Only minor differences were seen between the
two treatment groups (Table 1). In total, 28 patients were
later withdrawn from the study because of protocol
violations (n ¼ 6), withdrawn consent (n ¼ 5), lost at
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other causes (n ¼ 9) with similar distribution between the
two treatment arms. Accordingly, 103 patients in the FP
group and 98 patients in the BUD group completed the study
per protocol. By the observations during run-in 6/116 in the
FP group and 3/113 in the BUD-group were classiﬁed as
having mild asthma, and the rest of them as having
moderate asthma, according to GINA guidelines.9
Initiation of the therapy was both in the FP group and in
the BUD-group followed by signiﬁcant improvements
(Po0.001, Wilcoxon signed rank test) in mean values for
lung function, symptom scores and use of rescue medication
(Table 2).
Exacerbations
During the study period 147 (FP 76, BUD 72) non-infectious,
and 117 (FP 53, BUD 64) infectious, exacerbations were
diagnosed. Only 4 infectious exacerbations in the FP- and 7
in the BUD-group were followed by a second one within 6
weeks thus causing a dose deﬁning withdrawal. In the FP-
group 5 and in the BUD-group 4 prednisolone courses were
given among patients still remaining in the trial after an
infectious exacerbation. Thus, most infectious exacerba-
tions were mild, not needing oral steroid treatment.
At the end of step one 16% of the patients in the FP group
and 21% in the BUD group left the study because they never
reached stable asthma control as they experienced a dose
deﬁning exacerbation already during weeks 5–12. However,
a post hoc analysis showed that the mean values for PEF,
symptom score and rescue medication had improved800 600 400 200 0
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Figure 2 The frequency of exacerbations at the various dose
steps. The frequency is expressed as % among those at risk.
Numbers at risk at each dos step is indicated by ﬁgures in italics.
Table 3 Dose deﬁning exacerbations as diagnosed by PEF-reco
Exacerbation criteria All possible combinations Criterion as
FP BUD FP
PEF 12 18 7
Rescue medication 38 42 8
Symptom score 60 60 28
Note 1: data are missing for 4 patients in the FP and 2 in the BUD gr
Note 2: one exacerbation in the FP and 2 in the BUD group were diagno
criteria.signiﬁcantly at the end of step 1 also for these patients
although the improvement was less marked compared to
those still remaining in the study. At the following dose steps
the frequency of exacerbations then increased in a dose
dependent fashion (Pp0.0001 for FP and P ¼ 0.0156 for
BUD) as the dose was reduced (Fig. 2). In the FP-group
23/103, and in the BUD group 19/98, patients could quit
inhaled steroids and not get an exacerbation during the
following 8 weeks (Table 3).
Most of the dose deﬁning exacerbations were diagnosed
according to symptom scores or to symptom scores in
combination with PEF and/or rescue medication criteria
(Table 3). Only 15 exacerbations in each treatment group
were diagnosed on PEF or rescue medication criteria only.
The potency ratio between FP (Flixotide Diskus) and
BUD (Pulmicort Turbuhaler)
The primary end point, lowest efﬁcient maintenance dose,
could not be determined for 18 patients in the FP group and
for 24 patients in the BUD group as they did not reach the
predetermined criteria for asthma control during step 1
(Table 4). However, these patients still showed signiﬁcant
improvements in their asthma status although not reaching
full control. Assuming that a doubling of the dose would
have resulted in full control in these patients will yield a
potency ratio between Flixotide Diskus and Pulmicort
Turbuhaler of 1.75:1 (95% CI 1.26:1–2.43:1). Alternatively,
excluding these patients from the calculations gives a
potency ratio of 1.50:1 (95% CI 1.10:1–2.05:1).
Adverse events
The pattern of adverse events was similar in the two
treatment groups. The most frequently reported possibly
related adverse event was hoarseness (FP 3%, BUD 3%) and
oral candidiasis (FP o1%, BUD 2%).
Discussion
Using loss of asthma control (exacerbation) as the dose
deﬁning end-point we in this study found the therapeutic
potency ratio between FP (Flixotide Diskus) and BUD
(Pulmicort Turbuhaler) to be between 1.50:1 and 1.75:1
depending on if patients with insufﬁcient steroid-response
were excluded from the calculations or not. The ﬁrstrdings, rescue medication or symptom score.
single determinant PEF+ Rescue+ PEF+rescue+
BUD FP BUD FP BUD FP BUD
9 — — 0 0 — —
6 0 0 — — — —
21 2 3 27 30 3 6
oup with exacerbations diagnosed at unscheduled visits.
sed by the physician in spite of not fulﬁlling any of the diary card
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Table 4 Number of patients according to lowest
efﬁcient maintenance dose (mcg/day).
FP (n ¼ 103) BUD (n ¼ 98)
Dose n Dose n
4500 18 4800 24
500 25 800 13
200 11 400 14
100 13 200 15
50 13 100 13
0 23 0 19
B. Sta¨llberg et al.614alternative assumed all excluded patients to be resistant to
the treatment, which clearly was not true as they did
improve on treatment although not reaching full control.
However, we cannot exclude that these patients had some
steroid resistant components in their disease. Therefore, it
might not be correct to assume that all these patients had
reached full asthma control after doubling the dose in step
1, a fact that would move the calculated potency ratio from
1.75 towards somewhat lower values.
The second point (200mcg) in the dose–response curve
for FP clearly deviated from the rest of the curve (Fig. 2) in a
direction that shifts the calculated potency ratio from about
2 to lower values. We believe the high exacerbation rate
found at the dose step 200mcg for FP to be a by chance
ﬁnding. We feel that this conclusion is supported by the fact
that at this dose step 18/25 exacerbations in the FP group
were deﬁned according to a single criterion only, compared
to 28/80 at all dose steps together.
There are few other studies published comparing the
therapeutic efﬁcacy of FP and BUD based on dose–response
data. Two earlier studies, one in children10 and one in
adults,11 used a dose reduction design similar to the present
and did not ﬁnd any signiﬁcant potency difference between
FP and BUD. However, these studies differed from our study
in a number of aspects. They included only subjects with
proven asthma control on inhaled steroids, whereas our
study included steroid-naive asthmatics only. They used 5
weeks treatment periods compared to 8 weeks in our study.
Compared to our study the earlier study in children10 did not
include the lower daily FP dose (50mcg/day) and the earlier
study in adults11 did not include the two lower daily FP doses
(100 and 50mcg/day) as well as the lower BUD dose
(100mcg/day). To the best of our knowledge our study is
the ﬁrst dose–response comparison including daily metered
doses down to FP 50 and BUD 100 mg. The separation
between the dose response curves is most evident at the
lower daily doses (Fig. 2).
In a dose step up study in asthma patients formerly on
treatment with moderate to high doses of inhaled steroids
the relative efﬁcacy of FP and BUD on bronchial metacholine
PD20 reactivity was found to be 2.5.
12 However, the short
treatment periods, 2 weeks, make the results difﬁcult to
interpret, although it could be argued that too short
treatment periods should have similar consequences in the
two treatment arms.There are several published comparisons between FP and
BUD of clinical efﬁcacy using ﬁxed doses throughout the
study. Almost all of them have used doses (reviewed in)4,13
that are, at least in mild and moderate asthma, near or
above the top of the dose response curves, see Fig. 2.14,15
This fact will seriously impede potency comparisons be-
tween the drugs based on meta-analyses of pooled data
from such studies. The results will in this respect be largely
dependent on the doses chosen for the comparisons.4
The time-course for the onset of improvement in PEF and
symptom score was nearly identical for the two treatment
groups (data not shown) and similar to earlier published data
for FP16 and for BUD.17 The present study used a dose-
reduction technique and to the best of our knowledge there
is no detailed information available about the time-course
for the wearing off therapeutic effect upon cessation of
inhaled steroids, although signiﬁcant impairments have
been shown to occur within 2 weeks.18 We therefore used
relatively long, 8 weeks, treatment periods. Further, the
identical onset course for FP and BUD to our minds makes it
unlikely that the time-course for tapering off should differ
between the two drugs, thus hampering the potency
comparison.
This study did not include measures of systemic activity
because this has been extensively compared for FP and BUD
in several studies.4 Although the highest daily doses
used in this study have been demonstrated to affect various
biomarkers of systemic activity, there is no evidence
that these doses in adults may induce clinically relevant
side-effects like adrenal insufﬁciency, osteoporosis, skin
bruising or cataract.4 Thus, in the clinical situation it is
relevant to focus on the equipotent doses for therapeutic
effects.
The maximal therapeutic effect seems to have been
achieved already at a daily dose of 100–200 mg for FP and
200–400 mg for BUD (Fig. 2). This is in accordance with two
recent meta-analyses14,15 and supports the notion that mild
to moderate asthma should preferably be treated by low to
moderate daily doses of inhaled steroid. However, it must be
pointed out that the present results were obtained in
steroid-naive patients with mild to moderate asthma using
loss of asthma control as the dose-deﬁning end-point. The
dose response relationship is probably different in severe
asthma5,19,20 and may also be different using other end-
points as oral steroid sparing effect21–23 or tests of bronchial
hyperresponsiveness.12 The need for a balanced individua-
lized approach to dose selection of inhaled steroids in
asthma was illustrated in the recently published GOAL-
study.24 In this study, 70% of earlier steroid-naı¨ve patients
obtained well-controlled asthma on a 1-year treatment
course with inhaled FP in increasing daily doses up to 1000 mg
including a ﬁnal course with oral steroids. However, among
those who obtained well-controlled asthma, 82% did this on
an inhaled daily dose of 500 mg or lower.
Symptom score deﬁned the majority the exacerbations
both as single criterion and in combination with recordings
of rescue medication and/or PEF (Table 3). Only about 10%
of the exacerbations were deﬁned by PEF criteria only. The
agreement within the three criteria was clearly best
between symptom score and rescue medication, whereas
no exacerbation was deﬁned by a combination of rescue
medication and PEF (Table 3). These data cast some doubt
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symptom history to monitor the asthma disease state.
In conclusion, in steroid-naı¨ve patients with mild to
moderate asthma we found the therapeutic potency ratio
between FP (Flixotide Diskus) and BUD (Pulmicort Turbu-
haler) to be between 1.50:1 and 1.75:1 using loss of asthma
control as the dose deﬁning end-point. The potency
difference was evident only at low daily doses, below
200mcg. It should be pointed out that the present data
might not be valid for other drug–inhaler combinations.References
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